Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Author:
Umberto Vitolo,Juan Miguel Bergua Burgues,Johannes Duell,Michal Kwiatek,David Belada,Wojciech Jurczak,Marie Maerevoet,David Sibon,Richard Greil,Takahiro Kumode,Javier López-Jimenez,Caressa Meert,Juan-Manuel Sancho Cia,Catherine Thieblemont et al.
Publication:
The Lancet Haematology
Date:
Available online 12 June 2026
© 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.